Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease ...

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

Madam Goh, now 62, had thyroid eye disease (TED), a rare autoimmune disease in which the eye muscles and fatty tissue behind ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...

As previously announced, ACELYRIN held an End of Phase 2 (EOP2) meeting with the United States Food and Drug Administration (FDA) in Q3 2024 and gained alignment on the proposed LONGITUDE-1 and ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...

Topline data were announced from the phase 3 THRIVE-2 study evaluating veligrotug in patients with chronic thyroid eye ...

Acelyrin (SLRN) announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease. In the newly announced ...

Graves’ disease occurs when the thyroid gland becomes overactive and ... and treat each of them. Treatment for TED may include medications like steroids to reduce inflammation, an IV medication ...

Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced that Raymond Douglas, ...